Inviragen Merges With SingVax, Takes $15M

Fort Collins, Colorado-based Inviragen, a developer of vaccines for infection disease, said this week that it has merged with SingVax, and raised $15M in a Series A investment. According to the firm, the investment came from Charter Life Sciences, Venture Investors, Bio*One Capital, and Phillip Private Equity. The combined firm will continue to be known as Inviragen, and will have its research and operations in Fort Collins, the firms said, along with operations in Singapore and Madison Wisconsin. The firms lead compound is a vaccine protecting against dengue fever. The firm said the funding will cover Phase 1 and 2 clinical testing of its lead investments, as well as covering operations until 2012. More information »